March 14, 2016
USPTO issues Notice of Allowance to Horizon Pharma for VIMOVO
United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Horizon Pharma for U.S. patent application number…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 13, 2016
Sanofi and Regeneron in Phase 3 study shows sarilumab was superior to adalimumab for treating RA patients
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab…
March 10, 2016
Sanofi welcomes new Executive Committee member
Sanofi welcomes new Executive Committee member
March 10, 2016
Sanofi and MSD/Merck in joint vaccines operations in Europe
Sanofi and MSD/Merck in joint vaccines operations in Europe
March 10, 2016
Premaitha signs distribution agreement with GeNext in Russia
Premaitha signs distribution agreement with GeNext in Russia
March 7, 2016
Pharma crusader takes India’s drug regulators to court
One of India’s best-known whistleblowers, who exposed dangerous practices in the generic drug industry in 2013, is taking the country’s drugs regulators to court, accusing them of failing to enforce rules on drug safety in the $15 billion (11 billion pound) industry.
March 7, 2016
Lilly and Novartis reveal separate studies on plaque psoriasis
Good news for patients with moderate-to-severe plaque psoriasis. In only two days two big pharmaceutical companies have issued press releases about…
February 22, 2016
FDA Accepts Sanofi NDA for Combination of Insulin Glargine and Lixisenatide (diabetes)
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Sanofi’s investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes.
February 19, 2016
AstraZeneca’s Brilique OK for marketing in EU
The European Commission has granted to AstraZeneca marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
February 17, 2016
Durvalumab granted BTD by FDA for cancer patients
AstraZeneca and MedImmune, its global biologics research and development arm, on Wednesday announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.